Clarke, N. W., Ali, A., Ingleby, F. C., Hoyle, A., Amos, C. L., Attard, G., . . . James, N. D. (2019). Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. Ann Oncol.
Styl cytowania ChicagoClarke, N W., et al. "Addition of Docetaxel to Hormonal Therapy in Low- and High-burden Metastatic Hormone Sensitive Prostate Cancer: Long-term Survival Results From the STAMPEDE Trial." Ann Oncol 2019.
Styl cytowania MLAClarke, N W., et al. "Addition of Docetaxel to Hormonal Therapy in Low- and High-burden Metastatic Hormone Sensitive Prostate Cancer: Long-term Survival Results From the STAMPEDE Trial." Ann Oncol 2019.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..